Schistosomiasis and Pulmonary Hypertension

Carregando...
Imagem de Miniatura
Citações na Scopus
Tipo de produção
bookPart
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Citação
Schistosomiasis and Pulmonary Hypertension. In: Humbert, M; Souza, R; Simonneau, G (eds). PULMONARY VASCULAR DISORDERS, v.41. BASEL: KARGER, 2012. p.143-148. (Progress in Respiratory Research)
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Schistosomiasis is the third leading parasitic disease in the world. It is present in 74 countries, infecting 200 million people. Each year 280,000 patients die because of the disease. One of its most severe complications is pulmonary arterial hypertension (PAH). Previous studies have shown that 5% of patients with hepatosplenic schistosomiasis develop PAH. It is believed today that the most prevalent cause worldwide of PAH is schistosomiasis. Specifics about schistosomiasis-associated PAH including epidemiological data, mechanisms of the disease, clinical and hemodynamic features, and modalities of treatment will be reviewed in this chapter. Copyright (C) 2012 S. Karger AG, Basel
Palavras-chave
Referências
  1. AZMY S., 1932, Journal of the Egyptian Medical Association, V15, P87
  2. Bilharz T, 1853, Z WISS ZOOL, V4, P454
  3. BOUREE P, 1990, B SOC PATHOL EXOT, V83, P66
  4. Chaves E, 1965, Hospital (Rio J), V68, P635
  5. CHAVES E, 1966, DIS CHEST, V50, P72
  6. Crosby A, 2010, AM J RESP CRIT CARE, V181, P279, DOI 10.1164/rccm.200903-0355OC
  7. Fernandes CJCD, 2010, J AM COLL CARDIOL, V56, P715, DOI 10.1016/j.jacc.2010.03.065
  8. Figueiredo C, 2004, AM J RESP CRIT CARE, V169, pA174
  9. Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009
  10. HADENGUE A, 1991, GASTROENTEROLOGY, V100, P520
  11. HATZ C, 1992, ACTA TROP, V51, P15, DOI 10.1016/0001-706X(92)90017-R
  12. Igreja RP, 2007, ANN TROP MED PARASIT, V101, P575, DOI 10.1179/136485907X229086
  13. Lapa M, 2009, CIRCULATION, V119, P1518, DOI 10.1161/CIRCULATIONAHA.108.803221
  14. Lapa Monica Silveira, 2006, Rev Assoc Med Bras, V52, P139, DOI 10.1590/S0104-42302006000300012
  15. Le Pavec J, 2008, AM J RESP CRIT CARE, V178, P637, DOI 10.1164/rccm.200804-613OC
  16. Loureiro R, 2004, ORAL SILDENAFIL IMPR
  17. Meira J, 1991, CLIN DOENCAS TROPICA, P401
  18. Pereira GA, 2002, T ROY SOC TROP MED H, V96, P427, DOI 10.1016/S0035-9203(02)90381-0
  19. Pozzan G, 2008, AM J RESP CRIT CARE, V177, pA443
  20. Prata A, 1991, DOENCAS INFECCIOSAS, P838
  21. Rich S, 1998, WORLD S PRIM PULM HY
  22. Richter J, 2000, ACTA TROP, V77, P111, DOI 10.1016/S0001-706X(00)00125-X
  23. Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
  24. Salanitri John, 2002, Australas Radiol, V46, P435, DOI 10.1046/j.1440-1673.2002.01100.x
  25. Shaw AFB, 1938, J PATHOL BACTERIOL, V46, P401, DOI 10.1002/path.1700460302
  26. Simmonneau G, 2004, J AM COLL CARDIOL, V43, p5S
  27. [Anonymous], 2009, J AM COLL CARDIOL, V54, P43
  28. Vennervald BJ, 2004, CURR OPIN INFECT DIS, V17, P439, DOI 10.1097/00001432-200410000-00009